However, contrary to reports describing increased anti-tumor activity and CAR T cell persistence following modifications in the IgG4 spacer to abrogate FcγR-binding in the CAR spacer domain (25, 27), we did not observe any in vivo therapeutic efficacy of IgG1 CAR T cells after similar modifications in our study. This evidence concerns the gene FCGR2A and neoplasm.